ArticlePharmaceutical statistics2022
Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.
Article in Pharmaceutical statistics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Evaluating Treatment Effects with Patient-Response-Related Outcomes in Comparative Clinical Trials.NEJM evidence · 2025Review
- An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties.Statistics in medicine · 2025Article
- Duration of Response as Clinical Endpoint: A Quick Guide for Clinical Researchers.Korean journal of radiology · 2024Article
- Inferences for the distribution of the duration of response in a comparative clinical study.Clinical trials (London, England) · 2024Article
- Comparison of Chemoembolization Outcomes Using 70-150 µm and 100-300 µm Drug-Eluting Beads in Treating Small Hepatocellular Carcinoma: A Korean Multicenter Study.Korean journal of radiology · 2024Article
- Estimation of the Restricted Mean Duration of Response (RMDoR) in Oncology.Pharmaceutical statisticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In oncology clinical trials, response-based endpoints (time to response, objective response, duration of response [DOR]) are commonly used to detect therapeutic effect to support proof-of-concept or submission decisions. The restricted mean DOR (RMDOR) was recently proposed as a composite nonparametric method to efficiently quantify the treatment effect related to tumor reductions, which offers an intuitive way to perform statistical inference in cross-arm comparison and has since been applied in some Phase III studies. In this paper, we provide further technical details and asymptotic properties of the RMDOR method and discuss the selection of the truncation time. A simulation study is conducted comparing the performance of the proposed method with existing standard methods in hypothesis testing and quantification of treatment efficacy. We use two oncology Phase III examples to illustrate the method. An R package PBIR and a SAS macro are available to perform statistical inference based on the RMDOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.